ascopubs.org

Peptide receptor radionuclide therapy (Lu-177 PRRT) in neuroendocrine tumors (NET) over 16 years: Single institution experience.

Clinical outcomes of [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) vs everolimus (EVE) in managing patients (pts) with gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): Real-world analysis of the PRIME ...
EurekAlert!

Intraarterial radionuclide therapy safe and effective for advanced meningioma patients

Transaxial slices of baseline positron emission tomography (PET) and fused PET/magnetic resonance imaging (MRI; left) demonstrate a somatostatin receptor-expressing meningioma in the left cavernous ...
Kaleido Scope

Rose featured on UAB MedCast

J. Bart Rose, M.D., MAS., an associate professor in the UAB Department of Surgery, joined UAB MedCast to discuss the complexity of neuroendocrine tumors (NETs) and the use of peptide receptor ...
ascopubs.org

Peptide receptor radionuclide therapy (Lu-177 PRRT) in neuroendocrine tumors (NET): Single institution experience over 15 years.

Combination of ZG005 with etoposide and cisplatin (EP) vs. EP as the first-line therapy for advanced neuroendocrine carcinoma: A randomized, multicenter, phase I/II trial. This is an ASCO Meeting ...